Abstract
5085 Background: Conventional dose chemotherapy is the standard salvage therapy for patients with progressive or relapsed germ-cell tumors (GCT). The IT94 phase III randomized trial compared conventional chemotherapy (4 cycles of cisplatin, ifosfamide, and vinblastine [VeIP]) with high-dose chemotherapy (3 cycles of VeIP followed by 1 cycle of high-dose carboplatin, etoposide, and cyclophosphamide [PEC]). Early serum tumor marker decline during chemotherapy was previously shown to predict survival in patients with poor prognosis disseminated non-seminomatous GCT in first line. The aim of this study was to assess whether serum tumor marker decline also correlates with outcome in the salvage setting. Methods: Serum tumor markers were obtained before chemotherapy and after two cycles of treatment from 235 patients accrued in the IT94 trial (114 and 121 in the 4VeIP and the 3 VeIP+PEC arms, respectively). The decline of serum alfa-fetoprotein (AFP) and human chorionic gonadotropin (hCG) was assessed and class...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
